22.626 articles found

NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS

PESYAN AMIR, BALANDRIN MANUEL M.

· 2009-03-18

Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy.

Cannas A, Solla P, Floris G, Tacconi P, Serra A, Piga M, Marrosu F, Marrosu MG.

J Neurol · 2009-03-18

DOI: 10.1007/s00415-009-0072-6PMID: 19319462

Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment.

Cuomo D, Martella G, Barabino E, Platania P, Vita D, Madeo G, Selvam C, Goudet C, Oueslati N, Pin JP, Acher F, Pisani A, Beurrier C, Melon C, Kerkerian-Le Goff L, Gubellini P.

J Neurochem · 2009-03-14

DOI: 10.1111/j.1471-4159.2009.06036.xPMID: 19519781

Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum.

Kong M, Ba M, Song L, Liu Z.

Neurochem Res · 2009-03-13

DOI: 10.1007/s11064-009-9939-2PMID: 19283475

QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS

LANSBURY JR. PETER T, JUSTMAN CRAIG J, FREDENBURG ROSS A, MERAY ROBIN KATE, DUGGAN MARK E, LIN PETER.

· 2009-03-12

QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS

LANSBURY PETER T, JUSTMAN CRAIG J, FREDENBURG ROSS A, MERAY ROBIN KATE, DUGGAN MARK E, LIN PETER.

· 2009-03-12

Semantic activation in Parkinson's disease patients on and off levodopa.

Angwin AJ, Arnott WL, Copland DA, Haire MP, Murdoch BE, Silburn PA, Chenery HJ.

Cortex · 2009-03-11

DOI: 10.1016/j.cortex.2009.02.012PMID: 19356748

TREATMENT OF INFLAMMATORY CONDITIONS AND DISEASES WITH METAL-THIOLS

SAHA DHANONJOY, DOMENICO PHILIP.

· 2009-03-10

The neurogenic niche in the carotid body and its applicability to antiparkinsonian cell therapy.

López-Barneo J, Pardal R, Ortega-Sáenz P, Durán R, Villadiego J, Toledo-Aral JJ.

J Neural Transm (Vienna) · 2009-03-05

DOI: 10.1007/s00702-009-0201-5PMID: 19263191

Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT.

Proc Natl Acad Sci U S A · 2009-03-04

DOI: 10.1073/pnas.0806474106PMID: 19261853

Consideration of gene therapy for paediatric neurotransmitter diseases.

Rotstein M, Kang UJ.

J Inherit Metab Dis · 2009-03-03

DOI: 10.1007/s10545-009-1054-7PMID: 19259783

Methylphenidate for the treatment of Parkinson disease and other neurological disorders.

Auriel E, Hausdorff JM, Giladi N.

Clin Neuropharmacol · 2009-03-01

DOI: 10.1097/wnf.0b013e318170576cPMID: 18978488